/
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Our lead product candidate, CMP-002, has the potential to be the first disease-modifying therapy for the treatment of synaptic Ras GTP…
The business is unprofitable at the operating level (-1502.43% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 436.5% YoY with margins expanding 6639.9pp.
Negative free cash flow of -$30M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$4M
▲ +436.5% YoY
Net Income (TTM)
-$86M
▼ -55.2% YoY
Op. Margin
-1335.18%
▲ +6639.9pp YoY
ROIC
-85.20%
▲ +32.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▲ +35.2% YoY
Op. Cash Flow (TTM)
-$26M
▲ +35.1% YoY
Net Debt
-$97M
Net Cash Position
Cash & Equiv.
$99M
Continue Research